Acute Respiratory Distress Syndrome (ARDS) Pipeline Review, 2025

The global acute respiratory distress syndrome (ARDS) pipeline is advancing. Many research centers and biotech firms are creating new treatments for this serious disease. ARDS brings about severe failure of the lungs very fast because the fluid that fills the alveoli prevents oxygen from getting into the blood, causing inflammation and injury to different organs. Sepsis, trauma and pneumonia are the kinds of infections that most often result in ARDS.

ARDS is serious, comes about in difficult ways and there are few effective drugs to treat it, it is a major unsolved issue in medical care. Because of this, specialists in healthcare and medicine have begun several programs focused on producing cell therapies, biologics, monoclonal antibodies and other immunomodulators. These efforts contribute significantly to the drug research, clinical trials data, and pipeline insights for ARDS, and are closely monitored by research companies involved in drug R&D and drug development.

Acute Respiratory Distress Syndrome (ARDS) Pipeline Insights 2025: Report Scope

Covering 50+ drug candidates and 50+ companies, Fortune Business Insights has released its report “Acute Respiratory Distress Syndrome (ARDS) Pipeline Insights 2025”. The report spans a broad range of therapies across various stages of development, including preclinical research and Phase I, II, and III clinical trials. These therapies are organized by their type of molecule such as monoclonal antibodies, peptides, proteins and stem cells, plus their method of administration such as through a vein, under the skin and in the muscle. The report also covers medicines grouped according to whether they work alone or with additional medications. Besides, it includes data on drugs in pipeline that are not promoted, along with geographic facts in North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Besides summaries of ARDS products, the report offers market intelligence on licensing agreements, mergers and acquisitions, forms of collaboration and the overall competitive situation.

Reasons to Buy this Report

• Prepare robust business strategies by carefully studying the world’s ARDS pipeline review and the progress of ongoing drug research.
• Find major and emerging competitors in ARDS therapy and come up with methods to stay ahead.
• Learn more about the leading organizations’ main areas of focus and interest in ARDS treatment.
• Assess which companies may be acquired or partnered with based on how much research and development they do in ARDS.
• Introduce new strategies to increase and broaden R&D in the ARDS field, promoting continued growth for therapeutics in this market.
• Check the reasons why previous ARDS products were discontinued, so you can make changes in your R&D strategy.

Know Answers to Your Questions

• How many medications does each company have under development that are used for acute respiratory distress syndrome?
• How many drugs are being examined in phase 1 studies, phase 2 studies and phase 3 studies in the treatment of ARDS?
• Which significant collaborations between scientists and pharmaceutical companies, as well as mergers and license agreements, play a role in making this treatment available?
• How have recent advances and new tools been designed to fix issues with current therapies?
• What kinds of clinical trials are being carried out for acute respiratory distress syndrome and where are they in their progress?
• Which designations have been given to the upcoming drugs?

Report Methodology

• The data analysis and making of our ARDS pipeline reports depend heavily on credible desk sources. Moreover, we speak to key opinion leaders and specialists in the field as a part of what we consider secondary research.
• Sources for desk research include a variety of worldwide and regional clinical trial registries, company websites, annual reports, presentations for investors, press releases, news sites, white papers, documents from industry groups and databases or reports from the company or available on the web. This ensures comprehensive coverage of drug approvals, pipeline insights, and clinical trials results.

Clinical Trial Insights

The rising demand for effective therapeutic options in acute respiratory distress syndrome (ARDS) is propelling growth in the ARDS drug research and development landscape. Healthcare centers, members of the industry and research groups are organizing clinical trials to launch new drugs for ARDS. In addition, greater attention by government agencies on healthcare systems is aiding the growth of global clinical trial activities in this area. According to recent findings, scientists are investigating drug candidates for ARDS, as well as ways to make treatments safer and more reliable.

Acute Respiratory Distress Syndrome (ARDS) Pipeline Overview

Extensive development of different products has resulted from more government help and rising awareness of the condition. Multiple drug candidates are currently advancing through preclinical, discovery, and clinical phase 1 trials, phase 2 trials and phase 3 trials. To speed up advances and bring products to market, different companies are resorting to strategic purchases and partnerships, with top healthcare companies working on securing approval from the U.S. FDA to access the market.

Here’s a brief insight into some of the upcoming drugs in pipeline:

ExoFlo: Direct Biologics

ExoFlo is created using bone marrow mesenchymal stem cells (BM-MSCs) and is under study as a treatment for moderate to severe acute respiratory distress syndrome (ARDS), mainly in people with COVID-19. The treatment employs extracellular vesicles (EVs) from BM-MSCs to pass on their immunoregulatory and tissue-healing abilities to patients with ARDS. At present, a Phase III clinical trial is being conducted to evaluate the drug for the therapy of acute respiratory distress syndrome.

GEn 1124: GEn1E Lifesciences

GEn 1124 is a small molecule drug that is being developed by GEn1E Lifesciences and Biomedical Advanced Research and Development Authority (part of BARDA in the U.S. Department of Health and Human Services). It is designed for use in the ARDS therapy area and is in Phase II of its development.

ALT-100: Aqualung Therapeutics Corp.

This mAb therapy is meant to be given right when a patient is intubated and mechanical ventilation begins for respiratory failure. When infused into the blood, ALT-100 blocks the action of eNAMPT that may lead to too much inflammation, lowering the possible risk of dying from various inflammatory conditions, especially Acute Respiratory Distress Syndrome, Ventilator-Induced Lung Injury or Trauma-Induced Lung Injury. Today, the drug is undergoing Phase II clinical studies for acute respiratory distress syndrome.

Rhu-pGSN: BioAegis Therapeutics Inc

Recombinant human plasma gelsolin (Rhu-pGSN), developed by BioAegis Therapeutics, is being tested as a possible therapy for acute respiratory distress syndrome (ARDS) and severe COVID-19 infections. The drug is going through Phase II testing for acute respiratory distress syndrome.

AVM0703: AVM Biotechnology

AVM0703 is a special dexamethasone product from AVM Biotech that helps treat acute respiratory distress syndrome (ARDS) related to COVID-19 and influenza. Since the drugs work differently, it is now possible to use a high dose of dexamethasone which is usually limited by the risk of side effects at normal doses. Immediately after being given, AVM0703 encourages the body to produce and unleash these enhanced immune cells. Because they are designed to target and destroy infected or cancerous cells but not normal white blood cells, T cells may reduce the side effects faced by patients on chemotherapy. The drug is being tested in Phase I clinical trials for acute respiratory distress syndrome.